Browse courses by:
By: Mark R. Barakat, MD; Rishi Singh, MD
This course has expired. You can still review the content but course credit is no longer available.
Verteporfin for photodynamic therapy (PDT) has been approved for decades as a treatment for retinal disorders. Eye care professionals need to understand all the real-world clinical scenarios in which the use of PDT alone or in combination with anti-VEGF therapy can be a more efficacious treatment option than anti-VEGF monotherapy.
View this engaging webinar to gain insight into PDT treatment options as demonstrated with case examples presented by leading retina specialists.
Supported by a grant from Bausch + Lomb.
Upon completion of this activity, participants will be better able to:
Accreditation Statement
Evolve Medical Education LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Evolve Medical Education LLC designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Mark R. Barakat, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allegra, Alimera, Genentech, Novartis, and RegenXBio. Shareholder: Ohr, Oxurion.
Rishi Singh, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Carl Zeiss Meditec, Genentech, Novartis/Alcon and Regeneron Pharmaceuticals/Bayer. Grant/ Research Support: Apellis.
Editorial Support Disclosures, Erin K. Fletcher, MIT, director of compliance and education, Evolve; Susan Gallagher-Pecha, director of client services and project management, have no financial relationships with commercial interests. Jaya Kumar, MD, peer reviewer, has no financial relationships with commercial interests.